Please login to the form below
BACE inhibitor
This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck acquires pre-clinical biotech Calporta for up to $576m
Merck, among many big pharma players, has had its fair share of failure in the neurodegenerative research area – its lead BACE inhibitor verubecestat failed to show a clinical effect in
Latest news
-
Biogen and Eisai drop Alzheimer’s drug elenbecestat
Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... The sadly predictable pattern of the BACE
-
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
Novartis and Amgen researchers were well aware of these problems seen in earlier BACE inhibitor trials, but had not detected them in their own early trials. ... The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s
-
Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022
The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... BACE inhibitors are designed to an enzyme involved in the
-
Eisai to tackle dementia in new US research facility
Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and
-
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom
Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch table for September 2014
525. AstraZeneca / Lilly. Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
-
Pharma deals during September 2014
Rhizen to change their deal from a 50/50 joint venture to a global (excluding India) licence. The product, an oral PK13 delta inhibitor appears to have completed phase 2 the ... AstraZeneca and Lilly have announced a joint development and
-
Eisai: Bucking the trend with R&D growth
BACE inhibitor E2609.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- Building meaningful customer engagement through data-driven digital insights
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
